Alnylam expects to provide data out of this study in the third quarter of 2012. Indeed, ALN-TTR02 is our business lead program in this work and we expect to initiate a Phase II trial later on this year, accompanied by a pivotal trial starting in 2013,’ stated Akshay K. Vaishnaw, M.D., Ph.D., Senior Vice President and Chief Medical Officer of Alnylam. ‘ALN-TTR02 utilizes our proprietary second-generation LNP technology that has shown significant potency improvements in both pre-clinical and scientific studies. We quite definitely look forward to our anticipated reporting of TTR knockdown data from the Phase I study in the 3rd quarter of this yr.’ Related StoriesResearchers identify tumor suppressor genes that get subset of melanomasPerisylvian polymicrogyria gene foundUnderstanding how schizophrenia impacts workings of the mind’RNAi therapeutics represent a novel and thrilling approach for the treating ATTR, as this brand-new drug modality gets the potential to create a meaningful influence in the treating this devastating disease.The winning group from each college advanced to the semifinals, where eight finalists had been selected to contend at AMCP’s Annual Meeting & Expo. The 2015 recipients are: First place: Rutgers University Ernest Mario College of Pharmacy, with associates Danielle Tompkins, Alexander Mozeika, Ena Todorovska, Serena faculty and Arnouk advisor Saira A. Jan. The 1st place team’s college receives a $2,500 scholarship. Second place: Purdue University College of Pharmacy, with team members Hannah Han Le, Dong Helen Shao, Limin Zhang, Madeline faculty and Merkel advisor Amy Heck. The second place group’s college receives a $1,500 scholarship. Third Place: University of Minnesota University of Pharmacy, with associates Rebecca Pulk, Scott Baird, Mary Walter, Ryan faculty and Langem advisor Randall Seifert.